See more : JK Paper Limited (JKPAPER.BO) Income Statement Analysis – Financial Results
Complete financial analysis of In Veritas Medical Diagnostics, Inc. (IVME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of In Veritas Medical Diagnostics, Inc., a leading company in the Shell Companies industry within the Financial Services sector.
- Dah San Electric Wire & Cable Corp. (1615.TW) Income Statement Analysis – Financial Results
- Motorpoint Group Plc (MTPTF) Income Statement Analysis – Financial Results
- SC Health Corporation (SCPE) Income Statement Analysis – Financial Results
- YUKE’S Co.,Ltd. (4334.T) Income Statement Analysis – Financial Results
- AP Acquisition Corp. (APCA-UN) Income Statement Analysis – Financial Results
In Veritas Medical Diagnostics, Inc. (IVME)
Industry: Shell Companies
Sector: Financial Services
About In Veritas Medical Diagnostics, Inc.
In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with `near-patient' testing applications. Its primary product includes prothrombin monitor, which is used for the measurement of coagulation of blood in patients at risk of heart disease and stroke. The company's other products under development include predictor of labor onset, a consumer device for maternity planning; biomarker monitor for the measurement of a number of biomarkers, including heart attack, HIV, cholesterol, and cancer; blood glucose monitor, a noninvasive glucose concentration continuous bulk measuring device measurement; digital scanning machine, a noninvasive alternative to 2D X-ray scanning; osteoporosis detection and monitoring device, an instant display of bonemineral density for osteoporosis patients; and hand held digital strip reader for immunoassay applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. The company is based in Inverness, the United Kingdom.
| Metric | 2021 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.27M | 879.85K | 760.52K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 4.58K | 823.00 |
| Gross Profit | 0.00 | 0.00 | 1.27M | 875.27K | 759.69K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 99.48% | 99.89% |
| Research & Development | 0.00 | 711.33K | 1.31M | 1.16M | 561.69K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 107.80K | 2.01M | 1.06M | 1.95M | 1.19M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 107.80K | 2.72M | 2.23M | 3.14M | 1.77M |
| Cost & Expenses | 107.80K | 2.72M | 2.23M | 3.15M | 1.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 428.22K | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 8.32K | 16.44K | 27.93K | 21.75K |
| EBITDA | -107.80K | -2.71M | -983.38K | -2.24M | -995.08K |
| EBITDA Ratio | 0.00% | 0.00% | -48.47% | -259.53% | -360.36% |
| Operating Income | -107.80K | 2.72M | 959.06K | 2.27M | 1.01M |
| Operating Income Ratio | 0.00% | 0.00% | 75.45% | 257.52% | 133.33% |
| Total Other Income/Expenses | 0.00 | -953.11K | -889.74K | -184.97K | 0.00 |
| Income Before Tax | -107.80K | -3.67M | -1.85M | -2.45M | 734.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | -145.45% | -278.55% | 96.58% |
| Income Tax Expense | 0.00 | -5.44M | 889.74K | 184.97K | -1.75M |
| Net Income | -107.80K | -3.67M | -1.85M | -2.45M | 734.54K |
| Net Income Ratio | 0.00% | 0.00% | -145.45% | -278.55% | 96.58% |
| EPS | 0.00 | -0.06 | -0.03 | -0.05 | -0.09 |
| EPS Diluted | 0.00 | -0.06 | -0.03 | -0.05 | -0.09 |
| Weighted Avg Shares Out | 86.05M | 59.15M | 55.09M | 52.54M | 11.86M |
| Weighted Avg Shares Out (Dil) | 86.05M | 59.15M | 55.09M | 52.54M | 11.86M |
Source: https://incomestatements.info
Category: Stock Reports